共 123 条
[1]
Ikoma N(2016)Yield of staging laparoscopy and lavage cytology for radiologically occult peritoneal carcinomatosis of gastric cancer Ann Surg Oncol. 23 4332-4337
[2]
Blum M(2017)Patterns of initial recurrence in gastric adenocarcinoma in the era of preoperative therapy Ann Surg Oncol. 24 2679-2687
[3]
Chiang YJ(2014)Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors Int J Cancer. 134 622-628
[4]
Ikoma N(2022)Patterns of gastric cancer metastasis in the United States Am J Surg. 224 445-448
[5]
Chen HC(2022)Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Lancet Oncol. 23 234-247
[6]
Wang X(2021)First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial Lancet. 398 27-40
[7]
Thomassen I(2022)Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08) Gastric Cancer. 25 235-244
[8]
van Gestel YR(2014)Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial J Surg Oncol. 110 275-284
[9]
van Ramshorst B(2011)Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial Ann Surg Oncol. 18 1575-1581
[10]
Sirody J(2023)Cytoreduction and HIPEC for gastric carcinomatosis: multi-institutional analysis of two phase II clinical trials Ann Surg Oncol. 30 1852-1860